Loading…
Vaxfab Enterprises (BSE 542803)₹66.50+1.64%Trading & Distributors
In the Jun 2026 quarter (consolidated), Vaxfab Enterprises reported sales of ₹0.39 Cr and net profit of −₹3.03 Cr. For the year to Mar 2026, sales were ₹131 Cr and net profit −₹4.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2023 | Dec 2024 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Sales | 4.16 | 45.76 | 55.03 | 15.68 | 15.67 | 0.39 |
| Expenses | 3.90 | 39.49 | 54.45 | 15.37 | 15.36 | 6.06 |
| Operating Profit | 0.27 | 6.37 | 0.72 | 0.34 | 0.34 | −5.66 |
| OPM % | 6.3% | 14.0% | 1.3% | 2.1% | 2.1% | −1,412.4% |
| Other Income | 0.07 | 0.08 | −3.41 | −3.36 | −3.36 | 3.38 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 |
| Profit before tax | 0.32 | 6.39 | −2.72 | −3.06 | −3.06 | −2.27 |
| Tax % | 18.1% | 0.0% | −16.6% | 5.2% | 5.2% | 33.7% |
| Net Profit | 0.25 | 6.39 | −2.27 | −3.23 | −3.23 | −3.03 |
| EPS (Rs) | 0.30 | 7.61 | −2.70 | −3.85 | −1.64 | −1.21 |
| Mar 2023 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 16.99 | 70.05 | 131 | 86.77 |
| Expenses | 16.05 | 70.19 | 136 | 91.24 |
| Operating Profit | 0.00 | 0.00 | −5.01 | −4.26 |
| OPM % | 2.7% | 0.1% | −3.7% | −4.9% |
| Other Income | 0.00 | 0.99 | 4.99 | −6.75 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 3.99 | 0.06 |
| Profit before tax | 0.00 | 0.99 | −2.99 | −11.11 |
| Tax % | 24.0% | 21.9% | 48.9% | — |
| Net Profit | 0.00 | 0.00 | −4.99 | −11.76 |
| EPS (Rs) | 0.45 | 0.57 | −2.35 | −9.40 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | — |
| Mar 2022 | Mar 2023 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1.00 | 8.01 | 40.08 |
| Reserves | 1.99 | 7.99 | 3.99 |
| Borrowings | 0.00 | 0.99 | 43.96 |
| Other Liabilities | 0.00 | 10.03 | 116 |
| Total Liabilities | 2.99 | 27.02 | 204 |
| Fixed Assets | 0.00 | 0.00 | 13.02 |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 12.03 | 23.06 |
| Other Assets | 2.99 | 13.99 | 168 |
| Inventories | 0.00 | 4.99 | 6.99 |
| Trade receivables | 1.01 | 4.01 | 109 |
| Cash & equivalents | 0.00 | 3.99 | 2.99 |
| Total Assets | 2.99 | 27.02 | 204 |
| Mar 2023 | |
|---|---|
| Cash from operating activity | 2.01 |
| Cash from investing activity | −12.01 |
| Cash from financing activity | 13.95 |
| Net cash flow | 4.01 |
| Free cash flow | 1.99 |
| CFO / OP % | 418.0% |
| Mar 2022 | Mar 2023 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 1,094 | 86 | 301 |
| Inventory days | 365 | 108 | 19 |
| Days payable | 0 | 222 | 298 |
| Cash conversion cycle | 1,461 | −26 | 24 |
| Working capital days | 2,461 | 2 | 17 |
| ROCE % | — | 5.0% | — |
For the Jun 2026 quarter, Vaxfab Enterprises reported sales of ₹0.39 Cr and net profit of −₹3.03 Cr. The operating margin was −1,412.4%.
Vaxfab Enterprises' sales for the year to Mar 2026 were ₹131 Cr; over the last twelve months they were ₹86.77 Cr.
Net profit for the year to Mar 2026 was −₹4.99 Cr, and −₹11.76 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−9.40.
Vaxfab Enterprises reported borrowings of ₹43.96 Cr at Mar 2026, against cash and equivalents of ₹2.99 Cr.
Cash from operations was ₹2.01 Cr in the year to Mar 2023; after capital spending, free cash flow was ₹1.99 Cr.